Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy”: Analysis of response by line of therapy” (Annals of Oncology (2020) 31(S4) (S472–S473), (S0923753420406507), (10.1016/j.annonc.2020.08.654))

S. V. Liu, F. De Braud, A. Drilon, R. C. Doebele, M. R. Patel, B. C. Cho, M. J. Ahn, C. H. Chiu, A. F. Farago, K. Goto, J. Lee, Y. Ohe, S. H.I. Ou, P. Cassier, D. S.W. Tan, G. A. Otterson, L. Veronese, S. Osborne, B. Simmons, S. Siena

Research output: Contribution to journalComment/debatepeer-review

Abstract

The organisers regret that the table presented in this abstract was incorrect. The correct table is as follows: [Table presented] The organisers would like to apologise for any inconvenience caused.

Original languageEnglish (US)
Pages (from-to)577
Number of pages1
JournalAnnals of Oncology
Volume32
Issue number4
DOIs
StatePublished - Apr 1 2021

Bibliographical note

Publisher Copyright:
© 2021 European Society for Medical Oncology

Fingerprint

Dive into the research topics of 'Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy”: Analysis of response by line of therapy” (Annals of Oncology (2020) 31(S4) (S472–S473), (S0923753420406507), (10.1016/j.annonc.2020.08.654))'. Together they form a unique fingerprint.

Cite this